A Clinical Study to Evaluate the Efficacy and | Clinical Research Studies Listing

A Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Recruiting

18 years - 75 years

All

Phase 2

4 participants needed

1 Location

Brief description of study

The objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Pulmonary Arterial Hypertension,PAH
Age: 18 years - 75 years
Gender: All

Male and Female, Age 18-75, diagnosis of symptomatic PAH,(Pulmonary Arterial Hypertension)

Updated on 04 Aug 2024. Study ID: 848470

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Brief description of study

Eligibility of study

Find a site

Interested in the study